Table 2.

Patient characteristics.

Patient	Age	Sex	Etiology of SBS	Initial body weight (kg)	Anatomical situation	Remaining length of small intestine	Last GI tract operation	Begin parental support	Begin Teduglutide (Shire Pharmaceuticals Ireland Limited, Dublin)	Weight start (kg)	Weight at assessment (kg)	Months of observation
1	30	F	Small intestine volvulus	49.1	Colon in continuity	120 cm	02/2013	03/2010	11/2014	49.6	59.8	27
2	82	F	Acute mesenteric arterial occlusion	55.7	Colon in continuity	20 cm	12/2003	01/2004	11/2014	55.7	55	27
3	26	F	Acute mesenteric arterial occlusion	95	Colon in continuity	45 cm	11/2014	11/2014	07/2015	95	88	20
4	31	F	Crohn’s disease	54	Ileostomy	40 cm	08/2010	08/2010	03/2015	54	60	23
5	57	M	Crohn’s disease	71.8	Ileostomy	Unknown	11/2003	11/2014	06/2015	71.8	66	19
6	57	F	Acute mesenteric arterial occlusion	49.6	Colon in continuity	15 cm	10/2009	11/2009	07/2015	49.6	51.3	18
7	69	F	Crohn’s disease	54.5	Colon in continuity	60 cm	07/2006	07/2006	10/2015	54.5	55.9	15
8	68	M	Crohn’s disease	89	Colon in continuity	80 cm	11/2008	09/2009	01/2016	89	98	13
9	68	F	Crohn’s disease	40	Colon in continuity	100 cm	01/2007	12/2015	12/2015	40	48.2	14
10	50	F	Uncontrolled bleeding from angiodysplasias	42	Colon in continuity	150 cm	Uncertain, but before 2010	12/2015	01/2016	43.5	45	13
11	29	F	Mesenteric venous thrombosis	65	Ileostomy	Unknown	06/2009	07/2009	02/2016	65	64.5	12
12	43	M	Crohn’s disease	89.3	Ileostomy	50 cm	12/2013	01/2014	08/2016	89.3	86.1	7
13	51	M	Acute mesenteric arterial occlusion	74	Colon in continuity	30 cm	03/2016	04/2016	10/2016	74	77	4
14	26	M	Crohn’s disease	48.6	Ileostomy	unknown	06/2005	08/2015	07/2016	48.6	49.3	8

GI, gastrointestinal; SBS, short bowel syndrome.